Identification of potential human pancreatic α-amylase inhibitors from natural products by molecular docking, MM/GBSA calculations, MD simulations, and ADMET analysis
PLOS ONE · 16.03.2023 · 18 (3) · e0275765
DOI: 10.1371/journal.pone.0275765 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 16.03.2023. Verfasst von Santosh Basnet und 4 weiteren Autor:innen. Beteiligte Einrichtung: Central Department of Chemistry, Tribhuvan University, Kirtipur, Kathmandu, Nepal. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Biological Products. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: http://www.ugcnepal.edu.np/uploads/notice/csmNgT.pdf.
Abstract (Originalsprache)
Human pancreatic α -amylase (HPA), which works as a catalyst for carbohydrate hydrolysis, is one of the viable targets to control type 2 diabetes. The inhibition of α -amylase lowers blood glucose levels and helps to alleviate hyperglycemia complications. Herein, we systematically screened the potential HPA inhibitors from a library of natural products by molecular modeling. The modeling encompasses molecular docking, MM/GBSA binding energy calculations, MD simulations, and ADMET analysis. This research identified newboulaside B, newboulaside A, quercetin-3-O- β -glucoside, and sasastilboside A as the top four potential HPA inhibitors from the library of natural products, whose Glide docking scores and MM/GBSA binding energies range from -9.191 to -11.366 kcal/mol and -19.38 to -77.95 kcal/mol, respectively. Based on the simulation, among them, newboulaside B was found as the best HPA inhibitor. Throughout the simulation, with the deviation of 3Å (acarbose = 3Å), it interacted with ASP356, ASP300, ASP197, THR163, ARG161, ASP147, ALA106, and GLN63 via hydrogen bonding. Additionally, the comprehensive ADMET analysis revealed that it has good pharmacokinetic properties having not acutely toxic, moderately bioavailable, and non-inhibitor nature toward cytochrome P450. All the results suggest that newboulaside B might be a promising candidate for drug discovery against type 2 diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Central Department of Chemistry, Tribhuvan University, Kirtipur, Kathmandu, Nepal.
- Central Department of Physics, Tribhuvan University, Kirtipur, Kathmandu, Nepal.
- Department of Physics, Kathmandu University, Dhulikhel, Nepal.
ORCID-Profile: Santosh Basnet, Tika Ram Lamichhane, Rajendra Adhikari
Förderung
- http://www.ugcnepal.edu.np/uploads/notice/csmNgT.pdf
Zitieren
APA
Basnet, S., Ghimire, M. P., Lamichhane, T. R., Adhikari, R., & Adhikari, A. (2023). Identification of potential human pancreatic α-amylase inhibitors from natural products by molecular docking, MM/GBSA calculations, MD simulations, and ADMET analysis. PLOS ONE, 18(3), e0275765. https://doi.org/10.1371/journal.pone.0275765
Vancouver
Basnet S, Ghimire MP, Lamichhane TR, Adhikari R, Adhikari A. Identification of potential human pancreatic α-amylase inhibitors from natural products by molecular docking, MM/GBSA calculations, MD simulations, and ADMET analysis. PLOS ONE. 2023;18(3):e0275765. doi:10.1371/journal.pone.0275765
BibTeX
@article{Basnet2023,
author = {Basnet, Santosh and Ghimire, Madhav Prasad and Lamichhane, Tika Ram and Adhikari, Rajendra and Adhikari, Achyut},
title = {Identification of potential human pancreatic α-amylase inhibitors from natural products by molecular docking, MM/GBSA calculations, MD simulations, and ADMET analysis},
journal = {PLOS ONE},
year = {2023},
volume = {18},
number = {3},
pages = {e0275765},
doi = {10.1371/journal.pone.0275765}
}
EUVIMED